-
Clover Biopharmaceuticals’ SCB-2019 Vaccine Proves Effective in Teenagers
•
China-based Clover Biopharmaceuticals Ltd (HKG: 2197) announced positive results from a global Phase II/III trial of its SCB-2019 (CpG 1018/Alum) COVID-19 vaccine in adolescents aged 12 to 17. The study demonstrated superior immune response in teenagers compared to young adults, reinforcing the vaccine’s efficacy. Study Highlights Global Regulatory StrategyClover Bio…
-
CStone Pharmaceuticals’ H1 2022 Revenue Jumps 229% on Drug Sales Growth
•
China-based CStone Pharmaceuticals (HKG: 2616) reported RMB 262 million (USD 49.4 million) in revenue for H1 2022, marking a 229% year-on-year (YOY) increase. The growth was fueled by strong sales of in-licensed drugs Ayvakit (avapritinib), Gavreto (pralsetinib), and ivosidenib, as well as royalties from Cejemly (sugemalimab). Drug Performance Commercial StrategyCStone’s…
-
Innovent Biologics’ H1 2022 Revenue Rises 15.3% on Drug Sales Growth
•
China-based Innovent Biologics, Inc. (HKG: 1801) reported RMB 2.24 billion (USD 326.4 million) in revenue for H1 2022, a 15.3% year-on-year (YOY) increase. Product sales reached RMB 2.04 billion (USD 297.3 million), up 10%, while R&D spending rose 22.5% to RMB 1.07 billion (USD 155.9 million). Net losses widened to…
-
Akeso Biopharma’s H1 2022 Revenue Rises 26.8% on Penpulimab Sales
•
China-based Akeso Biopharma (HKG: 9926) reported RMB 163 million (USD 23.8 million) in revenue for H1 2022, up 26.8% year-on-year (YOY), with losses amounting to RMB 692 million (USD 23.7 million). The growth was primarily driven by sales of its PD-1 inhibitor penpulimab, which generated RMB 297 million (USD 43.2…
-
Alpha Biopharma Completes EVEREST Trial for Zorifertinib in EGFR+ NSCLC with CNS Metastases
•
Shanghai-based Alpha Biopharma announced the completion of the last patient visit in the Phase II/III EVEREST study for its next-generation EGFR inhibitor zorifertinib, targeting EGFR mutation-positive non-small cell lung cancer (NSCLC) patients with central nervous system (CNS) metastases. Topline data is expected by the end of 2022. Study DetailsThe multi-regional…
-
eTheRNA Raises EUR 39M in Series B2 to Expand mRNA Services and Leadership
•
Belgium-based biotech firm eTheRNA has completed a Series B2 financing round, raising EUR 39 million (USD 38.9 million). The round was led by Moderna co-founder Kenneth Chien and Novalis Life Sciences LLC, with participation from existing investors including LSP (EQT Life Sciences), PMV, China’s Grand Pharma, Fund+, and Omega Fund.…
-
Sorrento Therapeutics’ Abivertinib Shows Positive Long-Term Data in NSCLC Trial
•
Sorrento Therapeutics Inc. (OTCMKTS: SRNE) announced positive long-term results for its third-generation EGFR inhibitor abivertinib in a pivotal trial for advanced non-small cell lung cancer (NSCLC). The study, conducted exclusively in China, enrolled 209 patients with EGFR-mutated lung cancer previously treated with first-generation EGFR inhibitors. Trial Results The data is…
-
Porton Biologics and Royaltech Med Partner on Bacterial and mRNA Drug Platforms
•
China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has partnered with Suzhou Royaltech Med Co., Ltd to establish bacterial (Listeria) and mRNA drug platform technologies. The collaboration aims to integrate both firms’ resources and capabilities, though financial terms were not disclosed. Company Profiles Strategic OutlookThe partnership will…
-
NMPA Suspends UCB’s Keppra Over Labeling Issues, Prompting Recall
•
The National Medical Products Administration (NMPA) has suspended approval for UCB’s Keppra (levetiracetam) concentrated solution after an overseas inspection uncovered inconsistent expiration date labeling. The decision affects batches manufactured and packaged abroad, with UCB initiating a voluntary recall and cooperating to resolve the issue. Company ResponseUCB announced the recall of…
-
Biocytogen and Merck KGaA Ink Global Deal for RenMice Platform Licensing
•
Sino-US contract research organization (CRO) Biocytogen Pharmaceuticals (Beijing) Co., Ltd has entered into a global licensing agreement with Germany-based Merck KGaA, granting Merck exclusive rights to its RenMice platform. The platform will be used to discover and develop human antibodies against unlimited drug targets, with Merck holding full rights to…
-
3SBio Inc. Reports H1 2020 Revenue of RMB 3.091B, Net Profit Up 6.19%
•
China-based 3SBio Inc. (HKG: 1530) reported its H1 2020 financial results, with revenue of RMB 3.091 billion (USD 451.5 million), a 0.51% decrease year-on-year (YOY). Net profits rose 6.19% YOY to RMB 955 million (USD 145.3 million). R&D investment increased 14.7% to RMB 294 million (USD 42.9 million). Core Products3SBio’s…
-
Betta Pharmaceuticals’ H1 2022 Revenues Rise 8.5% on Drug Sales Growth
•
China’s Betta Pharmaceuticals (SHE: 300558) reported RMB 1.25 billion (USD 182.5 million) in revenue for H1 2022, up 8.5% year-on-year (YOY). The growth was driven by strong sales of key drugs, including icotinib and ensartinib, despite a 55.96% drop in net profits to RMB 95 million (USD 13.8 million). Drug…
-
Ranok Therapeutics Doses First Patient in RNK05047 Study for BRD4-Targeted Cancers
•
Ranok Therapeutics Co., Ltd, a Hangzhou-based biotech firm, announced that the first patient has been dosed in the Phase I/II CHAMP-1 study (NCT05487170) of its lead drug candidate RNK05047 in the United States. The trial will evaluate the safety and optimal dosage of the potential first-in-class small-molecule degrader targeting BRD4…
-
CSPC Pharmaceutical’s SYS6006 mRNA Vaccine Shows Strong Safety and Efficacy in Trials
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has provided updates on its in-house COVID-19 mRNA vaccine SYS6006, which has completed six clinical trials demonstrating safety and efficacy across different age groups and vaccination scenarios. Trial Highlights Vaccine ProfileSYS6006 is designed with antigenic mutations targeting prevalent strains. Preclinical data show efficacy…
-
SinoMab Bioscience’s SN1011 Gets NMPA Nod for NMOSD Trial
•
Hong Kong-based SinoMab Bioscience Ltd (HKG: 3681) has received approval from the National Medical Products Administration (NMPA) to conduct a Phase II/III study of its tyrosine kinase (BTK) inhibitor SN1011 for neuromyelitis optica spectrum disorders (NMOSD). The trial is expected to enroll its first patient in Q1 2023. Drug ProfileSN1011…
-
Mabwell Bioscience Receives NMPA Approval for 6MW3511 Clinical Trial in Solid Tumors
•
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced that the National Medical Products Administration (NMPA) has approved a clinical trial for its drug candidate 6MW3511, targeting advanced solid tumors. The trial will evaluate the drug’s efficacy and safety in patients with advanced solid tumors. Drug Profile6MW3511 is a bifunctional…
-
Bio-Thera Solutions Receives NMPA Approval for BAT8008 Clinical Trial in Solid Tumors
•
Bio-Thera Solutions (SHA: 688177), a Guangzhou-based biotech firm, has received approval from the National Medical Products Administration (NMPA) to conduct a clinical trial for BAT8008, its antibody-drug conjugate (ADC) targeting solid tumors. This marks the fourth product from Bio-Thera’s pipeline to advance into clinical trials. Drug ProfileBAT8008 combines a recombinant…
-
BeiGene’s Tislelizumab Receives 11th NMPA Filing for First-Line Esophageal Cancer
•
BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced that the National Medical Products Administration (NMPA) has accepted a supplementary Biologic License Application (sBLA) for its PD-1 inhibitor tislelizumab, seeking approval for first-line treatment of unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC). This marks the 11th market…
-
Innovent Biologics Doses First Patient in Australia Trial for PD-1/IL-2 Bispecific Antibody IBI363
•
China-based Innovent Biologics, Inc. (HKG: 1801) announced that the first patient has been dosed in a Phase I clinical trial of IBI363, an in-house developed PD-1/IL-2 bispecific antibody (BsAb) fusion protein, in Australia. The trial will evaluate the safety, tolerability, and preliminary efficacy of IBI363 in patients with advanced solid…
-
Lee’s Pharma Expands Global Rights to Windtree’s KL4 Surfactant Products
•
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has expanded its licensing agreement with US-based Windtree Therapeutics, Inc. (NASDAQ: WINT), securing global exclusive rights to develop, manufacture, and commercialize KL4 surfactant products, including Surfaxin, Surfaxin LS, and Aerosurf. The revised deal, effective August 9, 2022, builds on the initial agreement signed…
